Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma

Hepatology

Volumn 42, Issue 5, 2005, Pages 1127-1136

  Djojosubroto, Meta W ^a   Chin, Allison C ^b   Go, Ning ^b   Schaetzlein, Sonja ^a   Manns, Michael P ^a   Gryaznov, Sergei ^b   Harley, Calvin B ^b   Rudolph, K Lenhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b GERON CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GRN 163; GRN 163 L; OLIGONUCLEOTIDE; TELOMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME REACTIVATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TELOMERE; TUMOR GROWTH; TUMOR XENOGRAFT;

ANAPHASE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DNA DAMAGE; DOXORUBICIN; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES; OLIGOPEPTIDES; TELOMERASE; TELOMERE; TRANSPLANTATION, HETEROLOGOUS;

EID: 30944442508     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20822     Document Type: Article

References (44)

1. Fecht WJ Jr, Befeler AS. Hepatocellular carcinoma: updates in primary prevention. Curr Gastroenterol Rep 2004;6:37-43.
2. Verucchi G, Calza L, Manfredi R, Chiodo P. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection 2004;32:33-46.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362:1907-1917.
4. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-791.
5. Youssef N, Paradis V, Ferlicot S, Bedossa P. In situ detection of telomerase enzymatic activity in human hepatocellular carcinogenesis. J Pathol 2001; 194:459-465.
6. Tahara H, Nakanishi T, Kitamoto M, Nakashio R, Shay JW, Tahara E, et al. Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res 1995;55:2734-2736.
7. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985;43:405-413.
8. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345:458-460.
9. Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher AB, et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A 1992;89:10114-10118.
10. Vaziri H, Schachter F, Uchida I, Wei L, Zhu X, Effros R, et al. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am J Hum Genet 1993;52:661-667.
11. Wright WE, Shay JW. The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol 1992;27:383-389.
12. Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ, et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999;97:527-538.
13. Reaper PM, di Fagagna F, Jackson SP. Activation of the DNA damage response by telomere attrition: a passage to cellular senescence. Cell Cycle 2004;3:543-546.
14. Wright WE, Shay JW. Cellular senescence as a tumor-protection mechanism: the essential role of counting. Curr Opin Genet Dev 2001;11:98-103.
15. Kim JH, Kim JH, Lee GE, Kim SW, Chung IK. Identification of a quinoxaline derivative that is a potent telomerase inhibitor leading to cellular senescence of human cancer cells. Biochem J 2003;373:523-529.
16. Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wientjes MG, et al. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res 2003;63:579-585.
17. Zaffaroni N, Lualdi S, Villa R, Bellarosa D, Cermele C, Felicetti P, et al. Inhibition of telomerase activity by a distamycin derivative: effects on cell proliferation and induction of apoptosis in human cancer cells. Eur J Cancer 2002;38:1792-1801.
18. Herbert BS, Pongracz K, Shay JW, Gryaznov SM, Shea-Herbert B. Oligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors. Oncogene 2002;21:638-642.
19. Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, Priepke H, et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 2001;20:6958-6968.
20. Gonzalez-Suarez E, Samper E, Flores JM, Blasco MA. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat Genet 2000;26:114-117.
21. Rudolph KL, Millard M, Bosenberg MW, DePinho RA. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 2001;28:155-159.
22. Greenberg RA, Chin L, Femino A, Lee KH, Gottlieb GJ, Singer RH, et al. Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell 1999;97:515-525.
23. Akiyama M, Hideshima T, Shammas MA, Hayashi T, Hamasaki M, Tai YT, et al. Effects of oligonucleotide N3′→P5′ thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res 2003;63:6187-6194.
24. Asai A, Oshima Y, Yamamoto Y, Uochi TA, Kusaka H, Akinaga S, et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res 2003;63:3931-3939.
25. Gryaznov S, Asai A, Oshima Y, Yamamoto Y, Pongracz K, Pruzan R, et al. Oligonucleotide N3′→P5′ thio-phosphoramidate telomerase template antagonists as potential anticancer agents. Nucleosides Nucleotides Nucleic Acids 2003;22:577-581.
26. Ozawa T, Gryaznov SM, Hu LJ, Pongracz K, Santos RA, Bollen AW, et al. Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. Neuro-oncol 2004;6:218-226.
27. Wang ES, Wu K, Chin AC, Chen-Kiang S, Pongracz K, Gryaznov S, et al. Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 2004;103:258-266.
28. Herbert BS, Gellert GC, Hochreiter A, Pongracz K, Wright WE, Zielinska D, et al. Lipid modification of GRN163, an N3′→P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 2005 May 23; [Epub ahead of print]. DOI: 10.1038/ sj.onc.1208760.
29. Satyanarayana A, Wiemann SU, Buer J, Lauber J, Dittmar KE, Wustefeld T, et al. Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. EMBO J 2003;22:4003-4013.
30. Wiemann SU, Satyanarayana A, Tsahuridu M, Tillmann HL, Zender L, Klempnauer J, et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J 2002;16:935-942.
31. Poon SS, Martens UM, Ward RK, Lansdorp PM. Telomere length measurements using digital fluorescence microscopy. Cytometry 1999;36:267-278.
32. Martens UM, Brass V, Engelhardt M, Glaser S, Waller CF, Lange W, et al. Measurement of telomere length in haematopoietic cells using in situ hybridization techniques. Biochem Soc Trans 2000;28:245-250.
33. Rogakou EP, Boon C, Redon C, Bonner WM. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 1999; 146:905-916.
34. Rappold I, Iwabuchi K, Date T, Chen J. Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-signaling pathways. J Cell Biol 2001;153:613-620.
35. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003;426:194-198.
36. Hao LY, Strong MA, Greider CW. Phosphorylation of H2AX at short telomeres in T cells and fibroblasts. J Biol Chem 2004;279:45148-45154.
37. Lee KH, Rudolph KL, Ju YJ, Greenberg RA, Cannizzaro L, Chin L, et al. Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Proc Natl Acad Sci U S A 2001;98:3381-3386.
38. Wong KK, Chang S, Weiler SR, Ganesan S, Chaudhuri J, Zhu C, et al. Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. Nat Genet 2000;26:85-88.
39. Lechel A, Satyanarayana A, Ju Z, Plentz RR, Schaetzlein S, Rudolph C, et al. The cellular level of telomere dysfunction determines induction of senescence or apoptosis in vivo. EMBO Rep 2005;6:275-281.
40. Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980;209:497-499.
41. Saretzki G. Telomerase inhibition as cancer therapy. Cancer Lett 2003; 194:209-219.
42. Plentz RR, Caselitz M, Bleck JS, Gebel M, Flemming P, Kubicka S, et al. Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma. HEPATOLOGY 2004;40:80-86.
43. Satyanarayana A, Manns MP, Rudolph KL. Telomeres and telomerase: a dual role in hepatocarcinogenesis. HEPATOLOGY 2005;40:276-283.
44. Lechel A, Manns MP, Rudolph KL. Telomeres and telomerase: new targets for the treatment of liver cirrhosis and hepatocellular carcinoma. J Hepatol 2004;41:491-497.